Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 112 clinical trials
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the …

measurable disease
cancer
anemia
cell transplantation
bone lesion
  • 4 views
  • 12 May, 2022
  • 71 locations
Bortezomib in Intrahepatic Cholangiocellular Carcinoma

This study evaluates the efficacy and safety of second-line treatment of bortezomib in advanced intrahepatic cholangiocarcinoma patients.Half of participants will receive bortezomib while the

measurable disease
cholangiocarcinoma
oxaliplatin
cisplatin/gemcitabine
gemcitabine
  • 2 views
  • 25 Feb, 2022
  • 1 location
Isatuximab Lenalidomide Bortezomib and Dexamethasone in NDMM

This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.

platelet count
measurable disease
lenalidomide
dexamethasone
neutrophil count
  • 0 views
  • 01 Aug, 2021
  • 1 location
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

This protocol is a phase II multicenter, randomized, open label study designed to assess the efficacy and safety of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone (Dara

thalidomide
measurable disease
alkylating agents
cancer
anemia
  • 66 views
  • 12 Feb, 2022
Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma (BATMAN)

The purpose of this study is to determine whether bortezomib, cytarabine, and dexamethasone are effective in the treatment of relapsed or refractory mantle cell lymphoma after 1 to 3 lines of

refractory mantle cell lymphoma
mantle cell lymphoma
cytarabine
dexamethasone
neutrophil count
  • 13 views
  • 24 Feb, 2022
  • 1 location
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and

taxane
cish
doxorubicin
immunostimulant
cyclophosphamide
  • 1 views
  • 17 Oct, 2021
  • 1 location
Bortezomib and Temozolomide in Recurrent Glioblastoma With Unmethylated MGMT Promoter (BORTEM-17) (BORTEM-17)

This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and

platelet count
blood transfusion
recurrent glioblastoma
corticosteroids
karnofsky performance status
  • 48 views
  • 13 Feb, 2022
  • 2 locations
Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

This phase I trial studies the side effects and best dose of metformin and nelfinavir in combination with bortezomib in treating patients with multiple myeloma that has come back or does not

measurable disease
neutrophil count
immunoglobulin
immunoglobulin a
bone marrow plasma cells
  • 0 views
  • 04 Feb, 2022
  • 1 location
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE)

This phase II trial studies how well daratumumab, ixazomib, and dexamethasone with or without bortezomib work in treating patients with newly diagnosed multiple myeloma. Immunotherapy with

measurable disease
cancer
anemia
bone lesion
calcium
  • 0 views
  • 12 Feb, 2022
  • 1 location
CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma

Bortezomib and Dexamethasone in patients with Previously Treated Multiple Myeloma.

platelet count
dexamethasone
neutrophil count
bortezomib
  • 18 views
  • 28 Jan, 2022
  • 1 location